Gujarat Terce Laboratories Ltd.
Snapshot View

10.85 +0.51 ▲4.9%

26 July 2021, 04:00:00 P.M.
Volume: 16,343

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.gujaratterce.com
Financial Indicators
Market Cap 8.05 Cr.
Earnings per share (EPS) -0.64 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-06
Industry PE 35.25 Trailing Twelve Months Ending 2021-06
Book Value / Share 12.48 Trailing Twelve Months Ending 2021-06
Price to Book Value 0.87 Calculated using Price: 10.85
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.74 Cr. 7,420,300 Shares
FaceValue 10
Company Profile

Gujarat Terce Laboratories is engaged in the manufacturing of tablets, capsules, syrup and injections pertaining to the product group, pharmaceutical formulations and ayurvedic medicines. The company is selling its product in the domestic as well as international market.

The company’s registered office and factory are located at Bileshwarpura, Gandhinagar in Gujarat. Installed capacity of the company is 270 million tablets and 108 million capsules per annum.

Product list of the company includes:

  • Tablets
  • Capsules
  • Syrup
  • Injections

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.93%
1 Week
+15.43%
1 Month
+19.23%
3 Month
+51.96%
6 Month
+49.66%
1 Year
+27.95%
2 Year
+71.95%
5 Year
+13.26%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.25 1.79 2.22 0.83 -6.30 -0.15 2.65 4.07 2.52
Return on Capital Employed (%) 3.58 3.44 3.80 3.62 0.88 1.93 3.96 5.38 5.77
Return on Assets (%) 0.50 0.73 0.94 0.35 -2.66 -0.06 1.26 2.23 1.33

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 11 11 11 11 10 10 10 11 11
Non Curr. Liab. 9 8 8 8 8 8 2 2 2
Curr. Liab. 6 6 7 8 7 6 7 7 9
Minority Int.
Equity & Liab. 26 25 26 26 24 24 19 19 22
Non Curr. Assets 9 10 10 10 10 11 10 10 10
Curr. Assets 17 16 16 17 15 13 10 9 12
Misc. Exp. not W/O
Total Assets 26 25 26 26 24 24 19 19 22

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 99 79 29 26 25 25 29 31 38
Other Income 0 0 0 0 0 0 0 0 0
Total Income 99 79 29 27 25 26 29 31 38
Total Expenditure -98 -78 -28 -26 -25 -25 -29 -31 -37
PBIDT 1 1 1 1 0 1 1 1 1
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 -1 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -9 4 0 1 0 0 5 -1 -2
Cash Fr. Inv. 0 -1 0 0 0 0 1 0 0
Cash Fr. Finan. 8 -2 -1 -1 -1 0 -5 0 2
Net Change -2 1 -1 1 -1 0 0 -1 0
Cash & Cash Eqvt 1 2 1 2 0 1 1 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 35.23 35.23 35.67 35.67 35.67 35.74 35.74 35.74 35.85
Public 64.77 64.77 64.33 64.33 64.33 64.26 64.26 64.26 64.15
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 23 Jul 2021
Outcome Of Board Meeting
Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) read with Schedule III to the said Regulations this is to inform you that the Board of Directors of the Company at its Meeting held today i.e. Friday 23rd July 2021 which commenced at 11:00 a.m. and concluded at 12:30 p.m. inter alia have approved / noted the following:-

Fri, 23 Jul 2021
Audited Financial Results For The Quarter Ended On June 30 2021
Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) read with Schedule III to the said Regulations this is to inform you that the Board of Directors of the Company at its Meeting held today i.e. Friday 23rd July 2021 which commenced at 11:00 a.m. and concluded at 12:30 p.m. inter alia have approved / noted the following
Fri, 23 Jul 2021
Typographical Error In Financial Results For The Quarter Ended On June 30 2021
With reference to the above the Company has uploaded Financial Results for the quarter ended on June 30 2021 on July 23 2021 within the stipulated time. However the Company has erroneously mentioned the Basic and Diluted Earnings per Equity Share of Rs.-3.40 in the column of Unaudited Financial Results of June 30 2020 instead of Audited Financial Results of March 31 2021. Therefore please read the Basic and Diluted Earnings per Equity Shares as Rs.-3.40 in the column of Audited Financial Results of March 31 2021
Kindly ignore the typographical error and consider the Financial Results of the Company for the quarter ended on June 30 2021.

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Close Crossing 2 Year High Close Crossing 2 Year High
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%